HR Execs on the Move


 
ProNAi Therapeutics is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform for patients with cancer and hematological diseases. ProNAi`s lead DNAi product candidate, PNT2258, is designed to treat cancers that overexpress BCL2, an important and validated oncogene known to be dysregulated in many types of cancer. ProNAi is pursuing a multi-faceted clinical development strategy designed to efficiently achieve regulatory approval and maximize the commercial opportunity of PNT2258. ProNAi recently initiated "Wolverine", a Phase 2 trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.pronai.com
  • 2150 – 885 West Georgia Street
    Vancouver, BC CAN V6C 3E8
  • Phone: 604.558.6536

Executives

Name Title Contact Details

Similar Companies

International Stem Cell Corporation

International Stem Cell Corporation is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Chembio Diagnostic Systems

Chembio Diagnostic Systems, Inc. is a Medford, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Momenta Pharmaceuticals

Momenta is a biotechnology company with a product pipeline of both complex mixture generic and novel drugs. Our complex mixture generics and follow-on biologics effort is focused on building a thorough understanding of the structure-process-activity of complex mixture drugs to develop generic versions of marketed products. While we use a similar analytical and development approach across all of our product candidates, we tailor that approach for each specific product candidate. Our first objective is to apply our core analytical technology to thoroughly characterize the structure of the marketed product. By defining the chemical composition of multiple batches of a marketed product, we are able to develop an equivalence window which captures the inherent variability of the innovator`s manufacturing process. Using this information, we then build an extensive understanding of the structure-process relationship to design and control our manufacturing process to manufacture reproducibly an equivalent version of the marketed product. Where necessary, and as required by the U.S. Food and Drug Administration, or FDA, we will supplement an application with additional supportive structure-activity data (e.g., immunogenicity, pharmacodynamics). Our goal is to obtain FDA approval for and commercialize generic or follow-on versions of complex mixture products, thereby providing high quality, safe and affordable medicines to patients in need.

Great Lakes Drug Development

Great Lakes Drug Development is a Brighton, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.